The global pharmaceuticals industry has been on the front line of managing and treating the Covid-19 pandemic, and as a result has faced many challenges in reshaping how medicines are tested, manufactured, and brought to market. Overcoming these challenges has enabled organizations to unlock a level of agility and flexibility that had been previously untapped, and in doing so has introduced more effective operating models - many of which encompass increased or more sophisticated uses of technology.
The sector faces many of the same challenges as it did before the pandemic arrived, including some of the tightest regulations of any industry, new competition, and the end of patents for some blockbuster medications.
This paper looks to understand how pharmaceuticals organizations are tackling these challenges with automation; the key benefits and challenges associated with this, and their key drivers for greater transformation.
Becoming an agile enterprise means operating as a seamless mix of digital workers, human workers, and systems dynamically automating processes everywhere from the back office to the customer experience. You can do this with Blue Prism's intelligent digital workers that are versatile, autonomous, self-organizing, and secure. As a result, you gain better insight and control over the work, create new and transformative ways to operate, and empower people to focus on work that truly matters.
©2021 Blue Prism Limited. “Blue Prism”, the “Blue Prism” logo and Prism device are either trademarks or registered trademarks of Blue Prism Limited and its affiliates. All Rights Reserved.
If your network blocks YouTube, you may not be able to view the video on this page. In this case, please use another device. Pressing play on the video will set third-party YouTube cookies. Please read our Cookies Policy for more information.